We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+2.04%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$681M
AUM Growth
-$84.8M
Cap. Flow
-$23.2M
Cap. Flow %
-3.41%
Top 10 Hldgs %
54.41%
Holding
74
New
15
Increased
15
Reduced
15
Closed
16

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$38.2M
2
AUTL
Autolus Therapeutics
AUTL
+$15.6M
3
IMVT icon
Immunovant
IMVT
+$12.3M
4
IRON icon
Disc Medicine
IRON
+$12.1M
5
KROS icon
Keros Therapeutics
KROS
+$9.98M

Top Sells

Rank Stock Value
1
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$41.5M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$21.7M
3
TGTX icon
TG Therapeutics
TGTX
+$20.2M
4
CRDF icon
Cardiff Oncology
CRDF
+$13.2M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$9.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$2.38B
$106M 15.62%
6,480,000
-30,000
-0.5% -$578K
CMRX
2
DELISTED
Chimerix, Inc.
CMRX
$43.3M 6.36%
4,490,000
+533,500
+13% +$4.9M
TARA icon
3
Protara Therapeutics
TARA
$236M
$40.3M 5.92%
2,558,472
– –
BBIO icon
4
BridgeBio Pharma
BBIO
$15.4B
$36M 5.28%
+583,767
New +$38.2M
CDXS icon
5
Codexis
CDXS
$182M
$32M 4.71%
1,400,000
– –
ETON icon
6
Eton Pharmaceutcials
ETON
$1.79B
$29.6M 4.34%
4,040,000
– –
MGNX icon
7
MacroGenics
MGNX
$260M
$21.2M 3.12%
666,200
+295,600
+80% +$7.18M
TCON
8
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$20.7M 3.04%
125,919
– –
HROW icon
9
Harrow
HROW
$1.44B
$20.7M 3.04%
3,065,416
– –
CLDX icon
10
Celldex Therapeutics
CLDX
$3.18B
$20.3M 2.98%
985,000
-7,000
-0.7% -$161K
XOMA
11
DELISTED
Xoma
XOMA
$17.9M 2.62%
437,500
-17,500
-4% -$677K
STXS icon
12
Stereotaxis
STXS
$147M
$17M 2.49%
2,526,500
-494,936
-16% -$2.94M
NGNE icon
13
Neurogene
NGNE
$758M
$15.1M 2.22%
61,250
-8,065
-12% -$2.06M
FBIO icon
14
Fortress Biotech
FBIO
$93.4M
$13.7M 2.01%
258,333
-834
-0.3% -$47K
CYTK icon
15
Cytokinetics
CYTK
$10.8B
$13.5M 1.98%
580,000
-2,800
-0.5% -$59.8K
AUTL
16
Autolus Therapeutics
AUTL
$628M
$12.1M 1.78%
+2,112,918
New +$15.6M
IRON icon
17
Disc Medicine
IRON
$3.17B
$11M 1.61%
+27,017
New +$12.1M
DCPH
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$9.95M 1.46%
222,000
– –
MCRB icon
19
Seres Therapeutics
MCRB
$49.7M
$9.8M 1.44%
15,000
-1,766
-11% -$813K
KROS icon
20
Keros Therapeutics
KROS
$223M
$9.69M 1.42%
+157,500
New +$9.98M
CKPT
21
DELISTED
Checkpoint Therapeutics
CKPT
$9.19M 1.35%
+292,596
New +$9.81M
PRQR icon
22
ProQR Therapeutics
PRQR
$327M
$8.61M 1.27%
+1,303,000
New +$6.66M
EPIX
23
DELISTED
ESSA Pharma
EPIX
$8.25M 1.21%
284,050
– –
AFIB
24
DELISTED
Acutus Medical Inc
AFIB
$8.22M 1.21%
614,990
-135,000
-18% -$3.04M
ADMS
25
DELISTED
Adamas Pharmaceuticals
ADMS
$8.02M 1.18%
1,670,600
+182,800
+12% +$955K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2021 Portfolio in Review

As of Q1 2021, Opaleye Management held 74 positions worth $681M, down 11% from $766M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Opaleye Management withdrew a net $23.2M in Q1 2021, closing 16 positions and reducing 15 holdings. Its most notable exit was Eidos Therapeutics, Inc. Common Stock, an estimated $41.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Opaleye Management opened a new position in BridgeBio Pharma worth $36M.

  • Opaleye Management's largest Q1 2021 buy was BridgeBio Pharma: 583,767 shares worth $36M.
  • Opaleye Management added most to MacroGenics in Q1 2021, an estimated $7.18M increase.
  • Opaleye Management's biggest Q1 2021 reduction was Cardiff Oncology, cutting an estimated $13.2M.
  • Opaleye Management fully exited Eidos Therapeutics, Inc. Common Stock in Q1 2021, selling an estimated $41.5M.
  • Opaleye Management's ten largest holdings make up 54% of its $681M portfolio in Q1 2021.
  • Opaleye Management opened 15 new positions and closed 16 in Q1 2021.
  • Opaleye Management's portfolio value fell 11% quarter-over-quarter to $681M.

Based on Opaleye Management's 13F filing for Q1 2021, filed 18 May 2021.